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Abstract 
 
Objective: To evaluate CBTp delivered by non-expert therapists, using CBT relevant 
measures.  
Methods: Participants (N=74) were randomised into immediate therapy or waiting list control 
groups. The therapy group was offered six months of therapy and followed up three months 
later. The waiting list group received therapy after waiting nine months (becoming the 
delayed therapy group).  
Results: Depression improved in the combined therapy group at both the end of therapy and 
follow-up. Other significant effects were found in only one of the two therapy groups 
(positive symptoms; cognitive flexibility; uncontrollability of thoughts) or one of the two 
timepoints (end of therapy: PANSS general symptoms, anxiety, suicidal ideation, social 
functioning, resistance to voices; follow-up: power beliefs about voices, negative symptoms). 
There was no difference in costs between the groups. 
Conclusions: The only robust improvement was in depression. Nevertheless, there were 
further encouraging but modest improvements in both emotional and cognitive variables, in 
addition to psychotic symptoms. 
Key words: cognitive-behaviour therapy; psychosis; randomised controlled trial 
 
Significant outcomes CBTp is effective in reducing depression in 
distressed, medication-resistant individuals 
with psychosis 
 CBTp can be effective when delivered by 
non-expert, but supervised, CBT therapists in 
an NHS setting  
 CBTp may be effective in different areas of 
functioning, but improvements may not be 
consistent across individuals or last beyond 
the end of therapy  
 
 
Limitations The study may have been underpowered due 
to drop-outs and missing data 
 Neither patients nor assessors were blind to 
allocated group 
 The therapy groups could not be combined 
for all outcomes, leading to different 
outcomes being powered unevenly  
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Background 
 
A number of randomised-controlled trials (RCTs) have established that cognitive-
behaviour therapy for psychosis (CBTp) can be efficacious1. Several manuals2,3 are available 
which describe in detail the methods used. Efficacy is clearest for the medication-resistant 
group4,5, and approximately fifty percent of such patients who undergo therapy can be 
expected to benefit6. This kind of therapy is highly acceptable to patients7, and studies have 
showed a continued improvement even after therapy is terminated8. This body of work has 
culminated in the British National Institute for Health and Clinical Excellence (NICE) 
guidelines, and the recent update,9 recommending that CBTp should be offered as an 
adjunctive treatment to medication to all individuals with psychosis. 
Previous trials have used outcome measures of symptom change, such as the Positive 
and Negative Symptom Scale (PANSS10), the Brief Psychiatric Rating Scale (BPRS11), or the 
Comprehensive Psychiatric Rating Scale (CPRS12), chosen to be compatible with those used 
in medication outcome studies13  While such an approach is in line with recent views that 
psychological and drug therapies achieve therapeutic gains through similar pathways14,15 , 
nevertheless key researchers in this area have advocated that CBTp is not a quasi-neuroleptic, 
and that main outcome measures should relate to distress and/or behaviour rather than 
symptom change16. Indeed, CBTp manuals stipulate that distress and disability, rather than 
symptom change, should be addressed2. Measures such as the PANSS are relatively poor at 
measuring distress17, and are therefore not the most suitable outcome measures for CBTp 
trials. More recent studies show that effect sizes in symptom change on the PANSS are 
modest at best1, and CBTp made no impact on relapse rates in a recent methodologically 
highly rigorous RCT18. In contrast, the largest effect size of all the CBTp trials so far (1.1) 
was reported in the one study19 that used a more targeted and psychologically meaningful 
outcome measure (compliance with voices).  
It is therefore timely to consider how we measure outcomes in CBTp. One strategy is 
to carry out efficacy trials in selected samples for specific therapeutic procedures. This was 
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demonstrated by Trower et al19 who targeted compliance behaviour in individuals with 
command hallucinations, and Fowler et al20 who targeted activity levels in an early psychosis 
group with poor social functioning. Another is to conduct effectiveness trials with an armoury 
of outcome measures to encompass the wide range of problems encountered in routine 
psychological services for individuals with psychosis. For instance, service users often report 
that symptoms can be less debilitating than other aspects of living with a psychotic disorder, 
such as social exclusion and stigma21 , emotional problems and difficulties with 
relationships22. CBTp manuals emphasise that an individualised formulation approach is 
central to CBTp, and as such therapy goals vary widely between patients. Therefore it is 
theoretically appropriate to use a wider range of outcome measures than just psychotic 
symptom change. 
In addition, few of the published trials have been set within routine clinical services. 
Most trials to date have either used expert therapists4, or implemented rigorous training 
procedures for their therapists with frequent supervision18,23 . The therapy has often been 
delivered within research settings, for the duration of the trial only. Strict suitability criteria 
meant that patients have been highly selected. One exception is the effectiveness trial reported 
by Farhall et al24, which targeted a prospectively recruited representative sample of patients as 
they entered a community mental health service. However, similarly to Garety et al18, patients 
entered the trial following an inpatient admission or exacerbation of symptoms, and both the 
CBTp and control groups improved significantly on presence of psychotic symptoms.  
 
Aims of the study 
The present trial aimed to evaluate CBTp in an outpatient clinic with non-expert, but 
supervised, clinicians, and widened the primary outcomes to include CBT relevant measures 
in addition to symptom severity and insight. CBTp relevant measures were identified as (i) 
emotional problems, suicidal ideation and self-esteem; (ii) general functioning; (iii) beliefs 
about voices and the controllability of thoughts; (iv) cognitive flexibility and executive 
functioning. This trial also included an economic evaluation.  
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Method 
 
Design & procedures 
Participants were recruited from referrals to the Psychological Interventions Clinic for 
Outpatients with Psychosis (PICuP), based in the South London and Maudsley Foundation 
NHS Trust (SLaM) in the UK.   
A waiting-list control design was followed, which is a type of design increasingly 
being used in the literature25.26. Patients were randomised to either the waiting list control 
group (treatment as usual; TAU) or to immediate CBTp by being entered into a computerised 
randomisation programme written by the statistician. Patients receiving TAU were also given 
therapy after having waited nine months in the waiting list group, becoming the delayed 
therapy group. A waiting-list control design, including a delayed therapy TAU group, was 
decided on before the trial started for several reasons: (i) for ethical considerations (to allow 
everyone referred  to the clinic access to treatment); (ii) to maximise referral rates; (iii) to 
minimise drop-outs; and (iv) to increase the power of our analyses. Medication dosages 
(initially and during the ensuing 18 months of the trial) were left to the decision of the treating 
psychiatrist, within the British National Formulary Guidelines. 
Assessments were carried out by five independent research workers (RE, PF, MC, 
KC, and KD) who were not involved in the therapy. There were insufficient resources to keep 
assessors blind to treatment condition, but they were all trained in the use of the assessment 
measures. 
Assessments 
Patients were assessed independently at four time points: at baseline, three months 
into therapy (not reported here other than for service use and costs), at the end of therapy (six 
months after baseline), and at a three months follow-up after the end of therapy (nine months 
after baseline). The delayed therapy group was assessed at three further time points i.e., three 
months into therapy (12 months after baseline, not reported here), at the end of therapy (15 
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months after baseline), and at a three months follow-up after the end of therapy (18 months 
after baseline). A wide range of assessments was administered to account for the fact that 
CBTp targets different problems for different individuals, depending on the individualised 
formulation and the person‟s goals for therapy. Areas assessed, based on potential target 
problems identified in Fowler et al2,  included psychotic symptoms, emotional problems, 
functioning (social and cognitive), beliefs about symptoms, and insight. An economic 
evaluation was also carried out. The order of presentation of assessment measures was 
counterbalanced across participants. The same order of presentation was kept for each 
participant at each time-point, as far as it was possible. 
(i) Psychotic Symptom measures: 
The Structured Clinical Interview for the Positive and Negative Syndrome Scale 
(PANSS10) was used to be consistent with other CBTp trials. Each item is rated by the 
assessor on a severity scale ranging from 1 (absence of psychopathology) to 7 (extremely 
severe). Three scores are derived: Positive Symptom Scores (possible range of scores: 7-49); 
Negative Symptom Scores (possible range of scores: 7-49); General Symptom Scores 
(possible range of scores: 16-112). 
(ii) Psychological measures of psychotic symptoms: 
Beliefs About Voices Questionnaire-Revised (BAVQ-R27):  
This 35 item self-report questionnaire measures beliefs about, and emotional and 
behavioural responses to, voices. Each item is rated on a 4-point scale ranging from 0 
(disagree) to 3 (strongly agree). The most relevant subscales for CBTp consist of 
„omnipotence‟ (e.g. „My voice is very powerful‟), and „malevolence‟ (e.g. „My voice is 
persecuting me for no good reason‟) beliefs (both six items with potential ranges of score 0-
18), and „resistance‟ (four items for emotion: e.g. „My voice frightens me‟ and five items for 
behaviour: e.g. „When I hear my voice usually I tell it to leave me alone‟; possible range of 
scores: 0-27). The remaining two subscales („benevolence‟ beliefs, and „engagement‟ with 
voices) were not included to reduce the number of analyses.  
Meta-cognitions Questionnaire (MCQ28):  
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This scale measures meta-cognitive beliefs and processes, and was included because 
of reports that psychotic patients score higher on this measure29. Only one of the five 
subscales was used, namely the “negative beliefs about the controllability of thoughts and 
corresponding danger” (16 items: e.g. „I find it difficult to control my thoughts‟ and „I worry 
about my thoughts‟). Items are scored from 1 (do not agree) to 4 (agree very much), with a 
possible range of scores of 16-64. 
(iii) Emotional problems 
Other psychological problems were assessed using the Beck Depression Inventory 
(BDI-II30; possible range of scores: 0-63), the Beck Anxiety Inventory (BAI32; possible range 
of scores: 0-63) and the Beck Suicidal Ideation Scale (BSI32; possible range of scores: 0-42). 
Higher scores represent more severe pathology on the three Beck scales. Self-esteem was 
measured using the Rosenberg Self-Esteem Scale33. The possible range of scores is 10-40, 
with higher scores indicating poorer self-esteem.  
(iv) Social and occupational functioning  
The Social and Occupational Functioning Assessment Scale (SOFAS34; possible 
range of scores: 0-100, with higher scores representing better functioning), was completed by 
both the independent assessor, and by the patient‟s care coordinator, to ascertain social 
functioning. Ratings were averaged when there were two scores available. 
In addition, the number of days spent in hospital in the nine months following 
randomisation was obtained from clinical notes for the TAU and immediate therapy groups. 
(v) Cognitive functioning: 
Cognitive functioning was assessed using the Brixton and Hayling Sentence 
Completion Tests35 (possible range of scores for both tests: 1-10, with higher scores 
representing better functioning) for executive functioning and cognitive flexibility 
respectively. The Quick Test36 was used to obtain a measure of verbal I.Q. at the baseline 
assessment. 
(vi) Insight: 
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Insight was measured using the self-report Insight Scale (IS37), which measures three 
dimensions of insight: „awareness of illness‟, „awareness of symptoms‟, and „awareness of the 
need for treatment‟. Item 4 („My stay in hospital is necessary‟) was excluded because all 
participants were outpatients. The remaining items from the „awareness of need for treatment‟ 
dimension were used to calculate a score for this subscale with equal weight to the other two 
subscales, allowing a total score to be calculated which has the same range (0-12) as the full 
IS. Higher scores on the IS indicate better insight.  
(vii) Economic evaluation: 
The number of contacts with therapists was centrally recorded. Other service use was 
measured for the three months prior to baseline assessment, and 3-, 6- and 9-month follow-up 
using the Client Service Receipt Inventory (CSRI38). The CSRI included health and social 
care services as well as informal care provided by family/friends specifically because of the 
patients health problems. Patients were asked how many times specific services had been 
used, and where relevant they were also asked to state the typical duration of service contacts. 
Unit costs were attached to the service use measures in order to generate service costs39. 
Therapy was costed using the unit cost of a psychologist (£77 per hour). Informal care was 
costed using a unit cost of a homecare worker as a proxy value. This was based on the 
assumption that in the absence of an informal carer paid help would be required to perform 
the same tasks 
 
Therapy 
Individuals received six months of therapy. CBTp was based on the Fowler et al 
manual2 (also see Kuipers et al4), and was carried out by CBT therapists (N = 31; median 
number of patients seen = 2; mode = 1; range 1-7) under the supervision of either EK or EP. 
Therapists were all trained in CBT, but the majority were not experts in CBTp and received 
no extra training apart from fortnightly supervision and access to reading materials. They 
were employed in other jobs (as clinical psychologists, nurses, or psychiatrists), and saw 
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PICuP patients during their Continuous Professional Development (CPD) sessions to develop 
their skills in CBTp. 
Sessions were carried out weekly or fortnightly, depending on the preference of the 
patient, for up to one hour. From the outset there was a specific emphasis on engagement and 
building a good therapeutic relationship. Flexibility from the therapist was key throughout the 
therapy to maximise engagement and fit in with the patients‟ needs. All interventions were 
formulation driven, and focused on the therapy goals of the patient. For a sizeable proportion 
of the group, the goals of the patients centred on emotional problems, despite the presence of 
positive symptoms. This reflects our clinical experience of doing CBTp, which targets distress 
rather than symptoms per se, whether the distress emanates from symptoms or from 
concurrent emotional disorders (see also Farhall24).     
Patients received an average of 16 sessions (range 8-28; median = 16), as 
recommended by the updated NICE guidelines 9. The number of sessions received by the 
immediate and delayed therapy groups were similar (median number of sessions in immediate 
group = 15, delayed group = 17, Mann-Whitney U test, U = 307.5, p = .2). A small, random 
selection of therapy sessions (n = 13) were taped and sent to an independent, experienced 
CBTp therapist to be rated for fidelity of treatment using the Cognitive Therapy Scale for 
Psychosis (CTS-Psy40). The mean rating was 40.7 (range 21-53) out of a maximum of 60, 
with 77% of the tapes scoring above the 50% mark (ie >30).  
  
Waiting list control 
Individuals randomised to the waiting list control group received TAU for the first 
nine months, which usually involved medication and case management in a local NHS 
community mental health team. After nine months everyone was offered six months of 
therapy, identical to the immediate therapy group.  
 
Participants 
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Referrals were deemed suitable for the trial if they were aged between 18-65 years, 
had at least one distressing and persistent positive symptom of psychosis (score of 3 or above 
on at least one of the positive symptoms items of the PANSS10, accompanied by reported 
subjective distress), and did not have a primary diagnosis of alcohol or substance abuse or of 
an organic condition. Only patients who had been stable on medication for a period of at least 
three months were included (if there had been a recent change in medication, the three months 
criterion did not apply if the change had been (i) a “downgrade” ie a switch from an atypical 
to a typical neuroleptic, or (ii) a “sideways” move ie a switch from one atypical to another, or 
from one typical to another. The three months criterion did apply to a switch from any 
neuroleptic to Clozapine). 
Patients who were suitable but were either unable to complete (e.g., due to language 
difficulties), or distressed by, the baseline assessments, were also excluded. Thirty per cent of 
referrals to PICuP (n = 74) were recruited into the trial (see Figure 1 for the CONSORT 
diagram) Thirty-six patients were randomised to the immediate therapy group, and 38 to the 
waiting list control group. 
Insert Figure 1 here – CONSORT diagram 
Power calculation 
The power calculation was carried out on the basis of a difference in reduction of 
total BPRS11 scores between a CBT group and a control group found by Kuipers et al4 (CBT 
group: mean reduction over trial period = 2.02, SD = 2.31; control group: mean reduction = 
0.46, SD = 2.15). This study was chosen to base our power calculations on because of the 
similarities in the sample (medication resistant group), and the therapy manual followed2.A 
sample size of 34 per group would be needed to detect an effect size of this magnitude or 
larger with 80% power and using a two-sided independent samples t-test at the 5% 
significance level.  
 
Statistical analyses 
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The objective of the statistical analyses was to compare outcomes between TAU and 
CBT arms at the end of therapy and at the three months follow-up. In order to improve the 
power of our group comparisons, outcome data from the delayed therapy group were also 
included in our analyses and were combined with the immediate group where possible. 
Although such a design is less straightforward to analyse, patients being in different groups at 
different times is not a problem per se. The main issue is whether it is justified to combine the 
groups. A key assumption that has to be met to allow the groups to be combined is that being 
on the waiting list (i.e. receiving „waiting list + CBT‟) was an equivalent treatment to starting 
CBT at the beginning of the trial (i.e. receiving „immediate CBT‟). We addressed this issue 
empirically by testing for outcome differences between „waiting list + CBT‟ and „immediate 
CBT‟ treatments and only combining the two groups if the relevant test was not statistically 
significant ie if there was no detectable effect of delaying the therapy. As long as this 
assumption is met the intervention effects assessed are the same as those obtained in standard 
RCT designs. 
For each outcome, all available data at all time points were used in the formal 
analyses. This meant that participants in the immediate CBT group contributed up to three 
measures per outcome (at baseline, six and nine months post baseline) while participants in 
the delayed therapy group contributed up to five values (at baseline, six, nine, 15 and 18 
months post baseline). The end of therapy was defined as six months after baseline for the 
immediate therapy group and 15 months after baseline for the delayed group. Three months 
follow up was at nine months after baseline for the immediate therapy group and at 18 months 
after baseline for the delayed therapy group.  
The analysis of our longitudinal design containing between-participant („waiting list‟ 
vs. „immediate CBT‟) and within-participant („waiting list‟ vs. „waiting + CBT‟) factors 
necessitated the use of linear mixed modelling. Pre-randomisation values were used as a 
covariate and post-randomisation values as the dependent variable. The analysis was an 
intention-to-treat analysis, with participants being analysed in the groups to which they were 
randomised, irrespectively of whether they complied with their allocated treatment. Linear 
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mixed modelling is a likelihood approach and therefore valid under the less restrictive 
assumption that the data are missing at random, unlike LOCF analysis, which has been 
discredited in the statistical literature for dealing with missing data41. The fixed part of the 
model further contained main effects of group („waiting list‟, ‟immediate CBT‟ or „waiting + 
CBT‟), time point (end of therapy or follow-up) and terms reflecting an interaction between 
these two factors. The interaction was always included since previous studies have shown that 
CBT effects can change between the end of therapy and follow-up8. Finally, in order to 
account for correlation between repeated measures the random part of the statistical model 
included intercepts that varied with participant.  
A possible carry-over effect of waiting list on CBT, or in other words an effect of 
delaying CBT, was assessed by statistically testing the difference between the immediate and 
the delayed CBT group at the end of therapy and follow-up time points.  If no evidence for 
such an effect could be found (no significant delay by time point interaction or delay main 
effect) then the immediate and delayed CBT groups were combined into a single, combined 
CBT group. If there was evidence of such an effect, the two CBT groups were kept separate. 
A significant effect was found for three of the 12 outcomes analysed (PANSS positive, 
Hayling Test, and MCQ, uncontrollability of thoughts). Not being able to combine the groups 
for all outcomes increased the complexity of the interpretations of our findings, since not all 
outcomes were assessed with the same power. Nevertheless, after careful consideration it was 
felt that this analytic strategy was preferable to analysing the groups separately for all 
outcomes, since we would have lost considerable power for 12 (80%) of our outcomes, 
because of 3 outcomes where the groups could not be combined. It would have also meant 
doubling the number of analyses carried out. 
One of our outcomes (BSI32) had a discrete distribution (range from 0 to 28) with few 
above zero values, and was therefore dichotomised (0=0 score, 1=score of 1 or above). 
Clearly a normal distribution could not be assumed and instead this outcome was analysed 
using a generalised linear mixed model (with Bernoulli distribution and logit link function). 
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As a result of this, group effects are measured by odds ratios comparing the odds of suicide 
ideation between the two groups. 
The number of days spent in hospital in the nine months after randomisation was 
compared between the waiting list and the initial CBT group using a Mann-Whitney U test. 
The (generalized) mixed model analyses used all the available data per participant 
and are based on the less restrictive assumption that missing outcome values occur at random 
(MAR). In our case this means that explanatory variables included in the models (earlier 
values of the outcome variable, therapy group and time) were allowed to predict missing 
values.  
The general significance level was set to 5%. To correct for two time-wise group 
comparisons per outcome the level for such group tests was set to 2.5%.  All analyses were 
carried out in Stata 9. 
 
Analysis of economic data 
Nine-month costs were compared between the immediate therapy and control group 
and the delayed therapy and control group, controlling for baseline cost differences. Due to 
missing data at some time points we imputed costs where necessary using costs from other 
time points (with the impute function in Stata which uses a best-subset regression method) in 
order to generate nine-month figures. Cost data are usually skewed due to a small number of 
patients using high cost services, such as hospital beds. To make valid comparisons between 
mean costs (which are the most useful measure) we therefore used bootstrapping (which does 
not rely on any specific distribution) with 10000 repetitions to produce 90% confidence 
intervals using the percentile method. 90% confidence intervals were used because we 
assumed that people are more prepared to commit a type 1 error (rejecting the null hypothesis 
of no difference in costs when it is true) with economic data compared to clinical data42. Costs 
were not formally linked to outcomes in the form of a cost-effectiveness analysis. Because the 
delayed therapy and control group were the same patients we used the cluster option in Stata 
for this comparison. Given that multiple outcome measures were used it was more appropriate 
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to conduct a cost-consequences analysis where costs are viewed alongside outcomes to 
provide an overall assessment of the intervention. 
  
Results 
 
Overall our sample was middle-aged (therapy group: mean = 34 (S.D. = 9.8); TAU 
group: mean = 39.6 (S.D. = 10.2)), with a preponderance of men (therapy group: 26 males 
and 10 females; TAU group: 20 males and 18 females), a fairly long history of illness 
(therapy group: median = 6 years (range = 0-28), number of days in hospital in the last five 
years: median = 32 (range = 0-703); TAU group: median = 7 years (range = 0-32), number of 
days in hospital in the last five years: median = 50 (range = 0-1186)), and an average IQ 
(therapy group: mean = 95.03 (S.D. = 13); TAU group: mean = 94.5 (S.D. = 12.6)). They 
were mostly single (86% and 76% in the therapy and TAU groups, respectively), with just 
over 40% being non-White (47% and 39.5% in the therapy and TAU groups respectively). In 
the therapy group 68% were on an atypical antipsychotic, 20% on Clozapine, 6% were on a 
typical antipsychotic, and 6% were unmedicated, with a median percentage of maximum dose 
= 50 (range = 8-100); in the TAU group 49% were on an atypical antipsychotic, 35% on 
Clozapine, 13% were on a typical antipsychotic, and 3% were unmedicated, with a median 
percentage of maximum dose = 50 (range = 8-125 (one participant had a daily dose that 
exceeded the maximum dose by 25%)). 
As expected from randomisation, the groups were similar in demographics (gender, 
age, marital status, ethnicity, IQ) and clinical characteristics (total number of days in hospital 
in the last five years, length of illness, medication dosages).Twenty-five patients in the 
therapy group (69%), and 31 in the TAU group (82%), had auditory hallucinations; 30 
patients in the therapy group (83%), and 30 in the TAU group (79%), had delusions; 19 
patients in the therapy group (53%), and 23 patients in the TAU group (60%), had both.    
Seventeen patients dropped out of therapy or the trial, 10 from the immediate therapy 
group, and seven from the TAU group. A further nine people dropped out or could not be 
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followed up by the assessors in the delayed therapy group (see Figure 1).  Such figures are 
comparable to other CBTp trials18,43, which typically range between 20-30%. Three patients 
who dropped out from therapy in the immediate therapy group had assessment data available 
at the end of therapy time point, and one at the follow-up time point. None of the participants 
who dropped out from therapy in the delayed therapy group had assessment data available at 
either time point.   
There were no significant differences between the patients who remained in the trial 
and those who dropped out in age (t = -.04, d.f. = 72, p = .9), IQ (t = -.39, d.f. = 66, p = .7), 
gender distribution ( 2 = .01, d.f. = 1, p = .9), length of illness (Mann-Whitney U = 4.14.5, p = 
.3), number of days in hospital in the last five years (Mann-Whitney U = 402, p = .2), or 
medication dosage (Mann-Whitney U = 367, p = .9). In addition, some patients were not able 
to complete all the measures at all assessment time-points, giving variable Ns across measures 
and time-points.  
At six months, five patients in the initial therapy group (20.8%), and eight patients in 
the control group (34.8%), had changed or stopped their medications at some stage in the 
preceding six months. At nine months a further four (17.4%) and five (19.2%) patients in the 
therapy and control groups respectively had changed or stopped their medication. In the 
delayed therapy group, four patients (16%) changed or stopped their medication during the 
therapy period, and one further person (3.6%) changed or stopped medication during the 
follow-up period. Since the number changing medications in the two groups were remarkably 
similar, especially in the comparisons between the control group and the combined CBT 
group, medication change did not qualify to be a confounder (all analyses were in fact redone 
with medication changes as a covariate, which did not change any of the results).  
The outcome raw data and Ns for each outcome are summarised in Table 1 and the 
results from the statistical analyses are described below. Estimated difference coefficients are 
reported with 95% confidence intervals [CIs] in parentheses. Effect sizes ( ) for continuous 
outcomes were calculated as the estimated difference divided by the baseline standard 
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deviation across both groups. Graphical representations of a selection of significant results are 
depicted in Figure 2. 
 The results are reported for the combined therapy group (ie when there was no 
evidence for an effect of delaying the therapy) unless otherwise specified. 
 
Psychotic symptoms  
PANSS positive symptom score: 
The comparison of the immediate and the delayed CBT group showed a main effect 
of delay for this variable (z = 2.3, p = 0.023). Therefore the immediate and delayed therapy 
groups could not be combined and the two therapy groups were analysed separately. A 
significant reduction in PANSS positive scores was found for the delayed therapy group 
compared to the waiting list control group, but not for the immediate therapy group, at both 
the end of therapy (delayed therapy: -2.8 [-3.9 - -1.6], p <.001, =.59; immediate therapy: -
.64 [-2.5 - 1.2], p = .51, =.13) and the follow-up (delayed therapy: -1.6 [-2.8 - -.40], p = 
.009, =.34; immediate therapy: -.53 [-1.4 - 2.4], p = .58, =.11). 
 PANSS negative symptom score:  
The group difference was not statistically significant at the end of therapy (-1.3 [-3.0 - 
.39], p = .13, =.27), but a significant reduction in PANSS negative scores in the combined 
therapy group compared to the waiting list control group emerged at the follow-up (-2.0 [-3.7 
- -.28], p = .023, =.41).  
  
Emotional problems: 
PANSS general symptom score: 
There was a significant reduction in PANSS general scores in the combined therapy 
group compared with the waiting list control group at the end of therapy (-3.1 [-5.8 - -.53], p = 
.019, =.45), but not at the follow-up (-1.2 [-3.9 - 1.4], p = .37, =.17).  
Beck scales 
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The BSI was transformed into a categorical variable, with those scoring 0 being 
assigned to the non-suicidal group, and those scoring above 0 being assigned to the suicidal 
group. 
At the end of therapy there was a significant reduction in both depression (-2.8 [-5.2 - 
-.46], p = .02, =.24) and anxiety (-3.2 [-5.7 - -.80], p = .009, =.28) in the combined therapy 
group compared to the control group, and reduced odds of being suicidal in the combined 
therapy group compared to the waiting list control group (OR=.09 [.02 - .53], p = .008). 
Depression was the only variable to remain significantly reduced in the combined therapy 
group compared to the control group at the follow-up (depression: -3.0 [-5.4 - -.65], p = .01, 
=.26; anxiety: -1.7 [-4.2 - .77], p = .18, =.15; suicidal ideation: OR=.32 [.07 – 1.6], p = 
.16).  
Self-esteem 
The group differences were not statistically significant at either time point (end of 
therapy: -1.2 [-2.6 - .18], p = .09, =.20; follow-up: -1.2 [-2.6 - .21], p = .09, =.20).  
 
Social and cognitive functioning 
Brixton and Hayling tests:  
There was a main effect of delay for the Hayling test (z = 2.2, p = 0.027), and the two 
therapy groups were analysed separately for this measure. No significant differences were 
found on the Brixton test at either time-point (end of therapy: .50 [-.18 - 1.2], p = .15, =.23; 
follow-up: .43 [-.22 - 1.1], p = .20, =.19). In contrast, at both time-points there were 
significant improvements on the Hayling test for the delayed therapy group compared to the 
waiting list control group (end of therapy: .92 [.30 - 1.5], p = .004, =.60; follow-up: 1.0 [.41 
- 1.6], p = .001, =.65), but not for the immediate therapy group (end of therapy: .08 [-.74 - 
.91], p = .84, =.05; follow-up: .17 [-.61 - .95], p = .67, =.11).  
SOFAS 
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There was a significant improvement in SOFAS scores in the combined therapy 
group compared to the waiting list control group at the end of therapy (6.0 [2.1 - 9.9], p = 
.002, =.49), but not at follow-up (2.9 [-1.0 - 6.9], p = .14, =.24). 
Number of days spent in hospital 
The number of days spent in hospital was only available for the nine months 
following randomisation, and not the nine months following therapy (ie there were no data 
available for the nine months following the delayed therapy group). There were no significant 
differences between the immediate and waiting list control groups on this variable (Mann-
Whitney U = 611.5; p = .19). 
 
Insight 
No statistically significant effects were found at either time-point (end of therapy: -
.03 [-.83 - .78], p = .95, =.01; follow-up: .10 [-.71 - .92], p = .81, =.03). 
 
Beliefs about symptoms 
Beliefs about Voices Questionnaire-Revised 
Malevolence: No statistically significant effects were found for this variable at either 
time-point (end of therapy: -1.4 [-2.9 - .08], p = .063, =.23; follow-up: -.44 [-2.0 - 1.1], p = 
.57, =.07).  
Omnipotence: No statistically significant effect was found for this variable at the end 
of therapy (-.91 [-2.5 - .65], p = .25, =.20), although a significant reduction in omnipotence 
scores in the combined therapy groups compared to the waiting list control group emerged at 
the follow-up (-2.4 [-4.0 - -.86], p = .002, =.53).   
Resistance: There was a significant reduction in resistance scores in the combined 
therapy group compared to the waiting list control group at the end of therapy (-3.5 [-5.7 - -
1.3], p = .002, =.56), but not at the follow-up (.33 [.07 - 1.5], p = .16, =.05). 
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Meta-cognitions Questionnaire (Negative beliefs about the controllability of thoughts)  
The immediate and delayed therapy groups could not be combined for this variable 
due to a main effect of delayed therapy (z = 3.1, p = 0.002), and the two therapy groups were 
therefore analysed separately. At both time points there were significant reductions in scores 
in the immediate therapy group compared to the waiting list control group (end of therapy: -
12.0 [-18.0 - -6.2], p < .001, =.94; follow-up: -7.0 [-12.8 - -1.2], p = .018, =.55), but not for 
the delayed therapy group (end of therapy: -3.6 [-7.7 - .45], p = .081, =.28; follow-up: 1.5 [-
2.5 - 5.5], p = .47, =.12). 
 
 
Economic evaluation 
The Client Service Receipt Inventory:  
Service use and costs (excluding the CBT itself) are shown in Table 2. The contacts 
relate just to those patients using specific services whilst the costs are for the whole group at 
each time point. Inpatient costs and informal care costs accounted for most of the total at each 
time point and in each group. The mean (SD) cost of CBT for those in the immediate therapy 
group was £939 (£508). Adding this to the cost of other services used in the nine months 
following the start of treatment results in a mean total cost for the immediate therapy group of 
£11775 (£11058), which is higher than the nine-month costs for the control group - £9651 
(£12162). However, this difference was not statistically significant (90% CI, -£2383 to 
£3345).  
The CBT costs for the delayed therapy group were £1013 (£639), resulting in a total 
for the nine months after the start of therapy of £8618 (£6092). Comparing this to the control 
condition costs revealed a non-significant cost difference (90% CI, -£1882 to £621). 
 
 
Discussion 
 
The aim of this trial was to evaluate the impact of CBTp delivered by non-expert, but 
supervised, clinicians on a wide range of outcomes. The results were not clear-cut, with some 
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variables improving in the immediate, but not the delayed, therapy group, while others were 
significant at one time point but not the other, rendering it difficult to make firm conclusions 
about which areas of functioning are ameliorated by CBTp. It is likely that these findings are 
a reflection of the fact that therapy goals vary widely between patients, and that the groups 
could not be combined for all outcomes, which, in addition to missing data, led to unevenness 
of power across different outcomes at different time points.  
Overall, the only robust improvement was in depression, where significant effects 
were shown in the combined therapy group at both the end of therapy and follow-up, 
replicating the recent Garety et al trial18. The cost analysis showed no differences between 
therapy and TAU groups. There were also further encouraging but modest improvements 
found in both emotional and cognitive variables, in addition to psychotic symptoms, although 
overall only 40% of our comparisons showed a significant difference.  
Enduring improvement were shown for positive symptoms of psychosis, as you 
would expect from a therapy that targets predominantly distress associated with positive 
psychotic symptoms. However, significant effects at both time points were found in the 
delayed therapy group only, suggesting improvements may not be consistent across 
individuals.  
Other areas targeted by CBTp, but seldom assessed in trials so far, namely the process 
of thinking rather than merely the content of thought, also showed enduring improvements. 
Thus, cognitive flexibility, as measured by the Hayling35, and negative beliefs about the 
danger associated with the uncontrollability of thoughts, as measured by the Meta-Cognitions 
Questionnaire28, were improved at both the end of therapy and the follow-up stage, and 
showed larger effect sizes (ranging from .55 to .94) than positive symptoms and depression 
(ranging from .24 to .59). This is potentially an important finding since so much of CBT 
consists of changing current patterns of thinking and how people relate to their thoughts and 
symptoms (e.g., „decentring‟44,45), rather than merely discussing the evidence for and against 
the veracity of their thoughts. This is especially the case in CBTp, where challenging 
delusions and the reality of people‟s experiences are contra-indicated, and much work is done 
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on process rather than content. Nevertheless, again the above effects reached significance in 
only one of the two therapy groups, and therefore may not be consistent across individuals.  
 There were a number of other significant findings at the end of therapy, which were 
consistent in both therapy groups, but which were not maintained three months later. Anxiety 
and suicidal thinking were both improved after six months of therapy, as were general 
symptoms of the PANSS10, and social and occupational functioning. Again, these gains would 
be expected with CBTp, which aims not just to decrease positive symptoms of psychosis but 
to reduce distress and disability2. Although these gains were no longer significant at the 
follow-up stage, it can be seen from Figure 2 that it appeared to be the control group which 
improved in the last three months, rather than the therapy group deteriorating to pre-therapy 
levels; the latter appeared to stay constant during the follow-up period (indeed this pattern 
was true for most variables, including those where significant differences remained). One 
possibility is that this pattern is merely a reflection of the cyclical nature of psychosis. Other 
studies have found it difficult to demonstrate significant enduring improvements in the 
therapy group against a backdrop of natural remission in the control group8,18. However, this 
explanation is less likely to be valid in a medication-resistant sample, who show residual and 
enduring distressing symptoms of psychosis. Furthermore, for many of the outcomes the 
improvements in the control group were seen in the last three months before starting therapy, 
following a fairly stable six months period. Another possibility is that the control group 
improved as a result of knowing they were about to receive therapy shortly, potentially 
suggesting that being on a time limited waiting list for therapy is a therapeutic tool in itself, 
akin to a placebo effect46. In addition, the input of the research assistants, who met with them 
to complete the assessments every three months, may also have been therapeutic. Indeed, 
Sensky et al8 found that befriending improved outcome, although the improvements were 
short-lived. 
Interestingly, emotional and behavioural response to voices was also altered at the 
end of therapy, such that resistance to voices was diminished. At the follow-up stage, beliefs 
about the omnipotence of voices became significantly reduced. These results suggest that 
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omnipotence beliefs and response to voices are important areas that can possibly be changed 
in CBTp, over and above the frequency of voices. Again this is potentially an important 
finding, since beliefs about voices are more predictive of distress than severity and frequency 
of voices47,48,49. A change in beliefs about voices also echoes the actual process of CBTp, 
since most of the therapeutic work concentrates on people‟s appraisals, and relationship with, 
their voices, with the aim of rendering them less distressing, rather than on changing the 
actual physical occurrence of hallucinations3,19. 
One unexpected finding was the reduction of negative symptoms at the follow-up 
stage, since CBTp tends to concentrate on the distress associated with positive, rather than 
negative, symptoms of psychosis.  However, CBTp does address depression and functioning, 
with which there is a certain degree of overlap. Indeed, it has been argued that negative 
symptoms are manifestations of underlying defeatist and negativistic cognitions50. It may be 
that while improvements in overall depressive symptoms appear immediately after therapy 
ends, knock-on effects on negative symptoms take more time to manifest, as has previously 
been found with other symptoms of psychosis8.    
It is noteworthy that insight was not changed by CBTp in this trial. It is unlikely that 
this lack of change was due to a ceiling effect, since insight in the traditional sense ie 
recognising that one has a mental illness, is not a prerequisite of CBTp, and was not a 
criterion for referral or selection into the trial. Indeed the mean scores on the Insight Scale 
(IS37) of the current sample were similar to the published norms for this population. Although 
some variants of CBTp have targeted insight specifically23, the CBTp model followed in the 
current study2 does not stipulate that patients should be encouraged to reconceptualise their 
psychotic experiences within a medical model. Rather, therapists work within the broad 
model of understanding that their patients present with51,52,,, attempting to modify it and 
enrich it with a more psychological framework, so that distress can be reduced. Gaining 
insight, in the sense of accepting a label of mental illness, is not always helpful to individuals 
in terms of reducing their distress53,54. Furthermore, Brett55 found that medical model 
appraisals of anomalous experiences were related to increased distress in a group of 
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undiagnosed and diagnosed individuals, while normalising and spiritual appraisals of the 
same experiences were related to less distress. Therefore an improvement in traditional 
„insight‟ with CBTp is perhaps neither to be expected nor desirable. It is possible that the use 
of a more sophisticated measure of psychological, rather than purely medical, insight, such as 
the more recently published Beck Cognitive Insight Scale56, would have captured changes 
with CBTp, as found by Granholm et al57. 
 
Limitations 
A number of methodological problems that are common in trials of psychological 
therapies also apply to this trial. The inclusion and exclusion criteria meant that only 
individuals who spoke good English, and were able to complete the assessments, were 
recruited. Furthermore, we depended on referrals to a psychological therapies clinic, who 
were motivated to attend and engage in therapy, rather than sampling from a representative 
sample of outpatients with psychosis. However, all psychological therapies clinics in routine 
NHS services operate this level of triage, regardless of type of disorder, since psychological 
treatment is a question of choice on the participant‟s part. As such, our sample was likely to 
be representative of people with psychosis seen in psychological therapies clinics.  
We were unable to look at potential therapist effects due to the small sample size and 
the large number of therapists, with the modal number of patients seen by therapists being 
one. Previous studies have found that therapist expertise contributes to the variance in 
outcome58, and therefore may have been a factor in this study.  
  There were a large number of analyses conducted on a relatively small sample, thus 
increasing the likelihood of Type 1 errors. The lower significance level of .025 was adopted 
to adjust for the two post hoc group comparisons carried out at the end of therapy and the 
follow-up stages, but a large number of variables were still tested at both time points. 
Adjusting for multiple outcomes was not appropriate in this case, since we had a-priori 
reasons for including a range of different variables, and the study was not powered for 
Bonferroni corrections, and would therefore have led to Type II errors. The specific aim of 
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this trial was to assess a wide range of outcomes, since it reflects the actual process of 
individualised, formulation-based CBTp. Therapists address what is on the patient‟s „problem 
list‟, which will differ extensively between individuals. Indeed, for some patients the 
emotional problems they face are more difficult to bear than their symptoms of psychosis, and 
Farhall et al24 also noted that a majority of their sessions had emotional problems as their foci. 
Therefore we would argue that measuring positive symptoms only as the main outcome of 
CBTp will not necessarily capture meaningful change for individuals, despite the fact that a 
narrow set of outcomes is the preferable statistical option. Future trials will need to 
circumvent this problem by the use of new measures which encompass a range of problem 
areas, such as CHOICE (CHoice of Outcome In Cbt for the psychosEs59), which was designed 
in consultation with service-users specifically to address more closely the aims of CBT and 
the outcomes of import to service-users. 
There were a number of further statistical limitations. As well as Type 1 errors, the 
small sample combined with missing data meant that power was low on some of the analyses, 
and may have led to Type II errors. This was especially the case for measures relating to 
hallucinations (such as the BAVQ-R), and where the therapy groups could not be combined. 
Second, the fairly high level of drop-outs means that there may have been a degree of 
selection in those who completed therapy and the assessments, despite the fact that they did 
not differ on any demographic variables. Although we carried out an intention-to-treat 
analysis, only a few of the people who dropped out from therapy consented to be assessed at 
the six and nine months time points, and most could not therefore be included in the analyses. 
It was not possible to determine patients‟ reasons for dropping-out, since ethical requirements 
meant that the protocol of the study specified that they could withdraw at any time without 
justifying their decision. 
A third statistical limitation was the amalgamation of the immediate and delayed 
therapy groups, although this procedure is increasingly being used in RCTs of psychological 
therapy25,26. This design was adopted from the outset, partly to increase power. However this 
meant that we had to assume that immediate and delayed CBT were equivalent. Extra model 
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assumptions were then required to deal with the increased number of repeated measures for 
participants originally allocated to the waiting list. We assessed effects of delaying CBT 
empirically and found no evidence of such effects for most outcomes, but such assessment 
might also have suffered from lack of power.  Furthermore, for some of the analyses where 
the groups could not be combined, the significant effects were found only in one of the two 
therapy groups. This may be especially problematic when the significant effects were found 
only in the within-participants comparisons (i.e., the delayed therapy group). This was the 
case for positive symptoms and cognitive flexibility. These latter findings therefore need to be 
interpreted with more caution than our other outcomes, as the significant improvements may 
have resulted from the combined effects of being on the waiting list and therapy, rather than 
therapy alone.  
There were a number of other methodological limitations, such as the lack of 
blindness of the independent assessors. Tarrier & Wykes60 demonstrated an inverse 
relationship in published CBTp trials between the design rigour, especially blindness, and the 
effect size found, although not all meta-analyses have found this61. The context of the current 
study, namely running a trial within a routine clinic setting, meant that the ecological validity 
of the findings was increased at the expense of some methodological rigour. Nevertheless, the 
lack of blindness limitation applies to the interview-based measures only (ie PANSS and 
SOFAS), since the remaining 10 measures were self-rated, and the majority of our findings 
are therefore not subject to this bias. Nevertheless, the patients themselves were not blind to 
group allocation, and the self-report data may therefore also reflect expectancies of change 
rather than equate with objectively measured change. 
The follow-up period was short i.e., three months, compared to some trials which 
have followed people up for two years or more. However the design of this study, where 
people were offered therapy after having been in the waiting list control group, prevented us 
from being able to carry out a more extensive follow-up. We also had no control over 
medication changes or stoppages. However, the medication changes were equally distributed 
across the groups, and were therefore not considered to be a confounding variable. All 
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analyses were in fact repeated including this variable as a covariate in the models, and did not 
impact on the findings. Lastly, no control therapy was included in this trial due to limited 
resources, which means that some of the observed effects may have occurred via non-specific 
factors in the therapeutic contact.   
 
Clinical implications 
Bearing in mind the limitations delineated above, this trial still has some tentative but 
encouraging clinical implications. First, the results suggest that CBTp may incur modest 
improvements on individuals‟ functioning in a number of different domains, which include 
emotional problems, beliefs about and response to voices, and thinking processes, in addition 
to positive and negative symptoms. They map onto what clinicians would identify as the 
primary targets in CBTp, which recognise that people with psychosis should be viewed as 
individuals with an intertwined set of difficulties rather than “walking illnesses”. The lack of 
a consistent picture of change across the two therapy groups for those outcomes where the 
groups were analysed separately may be a reflection of the individualised nature of CBTp, 
whereby improvements can only be expected to occur in those areas that are targeted in the 
sessions, which is likely to differ across individuals.  
Second, the findings suggest that CBTp can be effective with non-expert therapists 
delivering therapy in a routine, NHS outpatient service, at least in reducing depression. 
Efficacy trials, although influential in the current British NICE guidelines9, can nevertheless 
run the risk of being seen as irrelevant by clinicians, because of the perceived gulf between 
research settings and the constraints experienced during routine clinical work. It is hoped that 
the current trial goes towards bridging this gap. However, it should be noted that although no 
specific training was given for the purposes of the trial, our therapists were all previously 
trained in general CBT, and received ongoing fortnightly group supervision throughout 
therapy. Furthermore, they had protected time as part of their CPD for their cases and for 
supervision. There is increasing evidence that attempts to deliver complex therapies such as 
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CBTp by care-coordinators or staff with limited training only, or by adequately trained 
therapists but without protected time or supervision, are not likely to be productive62. 
Third, our results provide some support for the previous and updated NICE 
guidelines9, which stipulate that CBTp works best for the „medication-resistant‟ group. All of 
our patients had ongoing distressing symptoms of psychosis, but were stable enough to be 
seen as outpatients. The median number of therapy sessions was 16, delivered over a period 
of six months, in line with the updated recommendations. Our results also add to the evidence 
base that the best use of limited CBT resources is to target help-seekers, rather than an 
unselected population18,24. 
Fourth, some of the improvements observed at the end of therapy were no longer 
significant three-months later. Potentially these results suggest that therapy should be 
augmented by booster sessions to ensure long-lasting results. However, as noted, for most 
variables the lack of significance at the follow-up appeared to be related to the control group 
improving in the last few months prior to starting therapy, rather than the therapy group losing 
their gains.  
Finally, the results of the cost analysis found no significant differences between 
groups, consistent with the updated NICE guidelines that also found that CBTp did not cost 
more. There was some suggestion that the costs of therapy may be offset by reduced costs of 
hospitalisation, but given the large standard deviations we need to be cautious about this 
finding. Carrying out cost analyses in trials is an important endeavour in the current climate of 
service providers in the UK and elsewhere, where the cost benefits of healthcare are under 
close scrutiny. Unfortunately, too often psychological therapies are seen as interventions 
which can only thrive in resource-rich times. However the present findings, in combination 
with previous studies9, suggest that such therapy need not add to overall costs in the NHS.  
 
To conclude, the results showed that the only robust and enduring improvements in a 
trial of CBTp carried out by non-expert therapists were in depression. Nevertheless, there was 
some support for further modest improvements in a number of other domains addressed by 
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CBTp. Both emotional (depression, anxiety, suicidal ideation), and cognitive (beliefs about 
voices, uncontrollability of thoughts, cognitive flexibility) variables, may be improved, in 
addition to psychotic symptoms, although these improvements may not be consistent across 
individuals and may not last once therapy has finished. There was no overall difference in 
costs between the groups, although this lack of difference may have been due to large 
variability across participants. . 
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Table1: Means, standard deviations, and Ns for the outcome variables in the immediate therapy, waiting list control, and delayed 
therapy groups. 
 
 
 
Immediate therapy group Control group Delayed therapy group 
 Baseline 
Mean (sd) 
N 
6 months 
Mean (sd) 
N 
9 months 
Mean (sd) 
N 
Baseline 
Mean (sd) 
N 
6 months 
Mean (sd) 
N 
9 months 
Mean (sd) 
N 
Baseline 
Mean (sd) 
N 
15 mths 
Mean (sd) 
N 
18 mths 
Mean (sd) 
N 
PANSS positive 17.1  
(4.7) 
36 
 
15.4  
(6.4) 
25 
16.1  
(6.0) 
23 
17.8  
(4.8) 
38 
17.4  
(5.4) 
30 
16.4  
(5.2) 
31 
17.8  
(4.8) 
38 
15.5 
(5.9) 
22 
14.8 
(5.1) 
19 
PANSS negative 11.1  
(4.2) 
36 
 
11.2  
(5.5) 
25 
11.0  
(4.7) 
23 
12.0  
(5.4) 
38 
12.8  
(6.0) 
30 
12.5  
(5.1) 
31 
12.0  
(5.4) 
38 
11.4 
(4.3) 
22 
10.2 
(4.5) 
19 
PANSS general 31.4  
(7.7) 
36 
 
28.0  
(6.5) 
25 
30.3  
(8.0) 
23 
30.8  
(6.2) 
38 
31.6  
(9.0) 
30 
29.8  
(7.3) 
31 
30.8  
(6.2) 
38 
29.3 
(7.4) 
22 
28.0 
(7.6) 
19 
Beck Depression Inventory 18.8 
(10.0) 
36 
 
17.6 
(11.5) 
20 
14.0  
(9.3) 
21 
21.3 
(13.1) 
38 
19.8 
(13.0) 
28 
19.0  
(13.0) 
30 
21.3 
(13.1) 
38 
17.6 
(13.4) 
22 
16.2 
(12.2) 
20 
Beck Anxiety Inventory 19.1  
(9.0) 
36 
 
14.9  
(9.3) 
22 
15.0  
(9.4) 
22 
20.0 
(13.7) 
38 
17.9 
(15.1) 
30 
16.0 
(13.9) 
30 
20.0 
(13.7) 
38 
15.6 
(13.6) 
22 
14.3 
(15.2) 
19 
Beck Suicidal Inventory 
[0 = scored 0 
1 = scored 1 or above] 
0 = 18;  
1 = 18 
36 
 
0 = 13 
1 = 7 
20 
0 = 11 
1 = 9 
20 
0 = 22 
1 = 16 
38 
0 = 13 
1 = 17 
30 
0 = 15 
1 = 15 
30 
0 = 22 
1 = 16 
38 
0 = 14 
1 = 8 
22 
0 = 13 
1 = 6 
19 
Rosenberg Self-Esteem Scale 25.6 
(5.9) 
36 
24.4 
(6.5) 
22 
24.4 
(6.6) 
22 
25.2 
(6.4) 
38 
25.5 
(6.1) 
29 
24.6 
(4.7) 
28 
25.2 
(6.4) 
38 
25.3 
(5.3) 
22 
23.6 
(5.3) 
20 
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Brixton test 5.3 
(2.2) 
36 
 
6.2 
(2.4) 
12 
6.8 
(2.4) 
16 
4.6 
(2.2) 
38 
4.6 
(2.8) 
22 
5.0 
(2.5) 
24 
4.6 
(2.2) 
38 
5.1 
(2.7) 
21 
5.0 
(3.2) 
19 
Hayling test 4.7 
(1.6) 
36 
 
5.1 
(1.3) 
11 
5.5 
(1.9) 
16 
4.9 
(1.5) 
38 
5.2 
(2.1) 
22 
5.5 
(1.4) 
25 
4.9 
(1.5) 
38 
6.6 
(1.4) 
19 
6.6 
(1.4) 
18 
Social & Occupational Functioning 
Scale (averaged when 2 scores 
available) 
63.2 
(11.5) 
35 
 
66.0 
(14.6) 
20 
64.7 
(11.1) 
19 
59.3 
(12.9) 
34 
57.3 
(11.3) 
29 
60.3 
(10.7) 
28 
59.3 
(12.9) 
34 
64.0 
(10.3) 
17 
66.6 
(13.4) 
18 
Days in hospital in 9 months post 
randomisation 
[Median; range] 
  6.4  
[0]   
[0-214] 
36 
  13.9  
[0]  
[0-273] 
38 
   
Birchwood Insight Scale 8.6 
(3.0) 
36 
 
8.3 
(3.7) 
22 
8.4 
(3.6) 
22 
8.5 
(3.4) 
38 
8.2 
(3.4) 
29 
8.2 
(3.6) 
30 
8.5 
(3.4) 
38 
8.1 
(4.2) 
22 
8.4 
(3.1) 
19 
Beliefs About Voices Questionnaire-
Revised (BAVQ-R); malevolence 
9.1 
(5.5) 
21 
 
7.5 
(5.7) 
10 
8.8 
(5.3) 
10 
9.8 
(6.5) 
26 
8.8 
(6.6) 
21 
9.4 
(6.7) 
22 
9.8 
(6.5) 
26 
7.7 
(7.2) 
15 
6.2 
(6.4) 
12 
BAVQ-R; 
Omnipotence 
9.6 
(4.2) 
21 
 
8.6 
(3.7) 
10 
7.7 
(4.2) 
10 
11.3 
(4.8) 
26 
8.4 
(6.5) 
21 
9.7 
(5.7) 
22 
11.3 
(4.8) 
26 
8.2 
(4.6) 
15 
6.1 
(4.9) 
12 
BAVQ-R; 
Resistance 
18.3 
(5.9) 
21 
16.6 
(7.3) 
10 
18.4 
(6.3) 
10 
18.2 
(6.6) 
26 
18.1 
(8.4) 
21 
17.1 
(8.2) 
22 
18.2 
(6.6) 
26 
15.1 
(7.5) 
15 
 
14.7 
(8.1) 
12 
Meta-Cognitions Questionnaire; 
controllability of thoughts 
44.0 
(11.0) 
25 
36.7 
(10.4) 
21 
39.6 
(8.9) 
20 
44.0 
(14.2) 
31 
45.8 
(14.6) 
26 
40.2 
(14.2) 
27 
44.0 
(14.2) 
31 
45.8 
(11.2) 
20 
40.3 
(14.5) 
19 
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 Table 2. Number (%) of patients using services, mean (sd) contacts by users and mean (sd) costs for whole sample. 
 
  Immediate therapy group 
 
Control group Delayed therapy group 
  0m 
 
3m 6m 9m 0m 3m 6m 9m 0m 12m 15m 18m 
Inpatient N 
Contacts 
Cost 
11 (31) 
49 (35) 
2985 
(5769) 
 
1 (5) 
91 (-) 
887 
(3968) 
1 (4) 
91 (-) 
772 
(3700) 
2 (10) 
21 (10) 
570 
(2002) 
8 (21) 
47 (27) 
1919 
(4415) 
2 (8) 
60 (45) 
893 
(3600) 
6 (20) 
39 (36) 
1542 
(4256) 
4 (14) 
56 (31) 
1560 
(4375) 
8 (21) 
47 (27) 
1919 
(4415) 
4 (17) 
21 (20) 
755 
(2154) 
3 (16) 
18 (24) 
609 
(5754) 
0 (0) 
- 
0 (0) 
Psych- 
iatrist 
% 
Contacts 
Cost 
27 (77) 
3 (3) 
251 
(287) 
 
14 (70) 
3 (2) 
219 
(291) 
17 (74) 
2 (1) 
154 
(128) 
14 (70) 
2 (1) 
172 
(209) 
31 (82) 
3 (3) 
253 
(262) 
17 (65) 
3 (2) 
196 
(194) 
20 (67) 
2 (1) 
147 
(173) 
21 (75) 
2 (1) 
129 
(111) 
31 (82) 
3 (3) 
253 
(262) 
16 (70) 
2 (1) 
126 
(115) 
15 (79) 
2 (1) 
173 
(233) 
11 (55) 
1 (1) 
108 
(221) 
GP % 
Contacts 
Cost 
15 (43) 
2 (2) 
25 (56) 
 
12 (60) 
3 (2) 
34 (49) 
12 (52) 
2 (2) 
18 (23) 
12 (60) 
1 (0.5) 
18 (20) 
23 (61) 
2 (1) 
28 (62) 
14 (54) 
2 (1) 
27 (34) 
16 (53) 
2 (3) 
23 (38) 
15 (54) 
2 (1) 
32 (44) 
23 (61) 
2 (1) 
28 (62) 
11 (48) 
2 (1) 
21 (31) 
9 (47) 
3 (2) 
28 (43) 
8 (40) 
2 (1) 
22 (40) 
Other 
doctor 
% 
Contacts 
Cost 
8 (23) 
2 (1) 
47 (104) 
 
2 (10) 
3 (2) 
24 (97) 
2 (9) 
1 (0) 
7 (25) 
4 (20) 
1 (1) 
24 (57) 
8 (21) 
2 (1) 
34 (76) 
2 (8) 
1 (0) 
4 (15) 
5 (17) 
2 (1) 
22 (59) 
7 (25) 
3 (3) 
53 (133) 
8 (21) 
2 (1) 
34 (76) 
4 (17) 
3 (1) 
50 (112) 
6 (32) 
1 (1) 
67 (154) 
4 (20) 
3 (1) 
54 (124) 
Day care % 
Contacts 
Cost 
11 (31) 
18 (14) 
104 
(251) 
10 (50) 
11 (16) 
121 
(387) 
7 (30) 
21 (22) 
173 
(477) 
 
8 (40) 
13 (13) 
71 (135) 
 
11 (29) 
26 (22) 
107 
(237) 
8 (31) 
36 (25) 
142 
(283) 
12 (40) 
22 (26) 
171 
(457) 
11 (39) 
24 (22) 
156 
(324) 
11 (29) 
26 (22) 
107 
(237) 
8 (35) 
27 (25) 
146 
(355) 
5 (26) 
35 (27) 
198 
(444) 
6 (30) 
26 (25) 
152 
(360) 
Social 
worker 
% 
Contacts 
Cost 
4 (11) 
2 (3) 
27 (119) 
4 (20) 
5 (5) 
71 (188) 
5 (22) 
4 (3) 
52 (150) 
5 (25) 
3 (2) 
53 (157) 
9 (24) 
5 (4) 
66 (162) 
4 (15) 
7 (4) 
115 
(332) 
8 (27) 
4 (4) 
54 (127) 
3 (11) 
2 (1) 
13 (45) 
9 (24) 
5 (4) 
66 (162) 
0 (0) 
- 
0 (0) 
0 (0) 
- 
0 (0) 
2 (10) 
2 (1) 
10 (39) 
CMHN % 
Contacts 
13 (37) 
8 (6) 
10 (50) 
6 (5) 
10 (44) 
7 (4) 
10 (50) 
4 (2) 
16 (42) 
6 (3) 
13 (50) 
7 (4) 
13 (43) 
6 (4) 
13 (46) 
6 (4) 
16 (42) 
6 (3) 
10 (44) 
6 (4) 
10 (53) 
7 (7) 
9 (45) 
4 (4) 
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Cost 118 
(238) 
116 
(208) 
121 
(169) 
 
59 (77) 92 (162) 117 
(165) 
122 
(194) 
83 (132) 92 (162) 70 (121) 118 
(212) 
66 (119) 
Therapist % 
Contacts 
Cost 
5 (14) 
5 (4) 
35 (124) 
0 (0) 
- 
0 (0) 
0 (0) 
- 
0 (0) 
4 (20) 
7 (4) 
99 (253) 
 
2 (5) 
8 (0) 
22 (97) 
1 (4) 
2 (-) 
2 (11) 
1 (3) 
1 (-) 
2 (11) 
1 (4) 
3 (-) 
6 (33) 
2 (5) 
8 (0) 
22 (97) 
1 (4) 
4 (-) 
10 (48) 
1 (5) 
4 (-) 
11 (47) 
1 (5) 
1 (-) 
3 (13) 
Medic- 
ation 
% 
Contacts 
Cost 
34 (97) 
- 
427 
(306) 
19 (95) 
- 
434 
(283) 
21 (90) 
- 
409 
(307) 
18 (94) 
- 
372 
(291) 
 
(90) 
- 
360 
(308) 
92 
- 
378 
(304) 
90 
- 
397 
(308) 
89 
- 
365 
(284) 
(90) 
- 
360 
(308) 
83 
- 
400 
(393) 
90 
- 
485 
(391) 
80 
- 
495 
(410) 
Informal 
Care 
% 
Contacts 
Cost 
21 (60) 
8 (12) 
905 
(1955) 
13 (65) 
4 (4) 
589 
(706) 
13 (57) 
12 (10) 
1275 
(1798) 
13 (65) 
14 (25) 
1809 
(4062) 
 
18 (47) 
8 (10) 
780 
(1574) 
16 (62) 
9 (10) 
1111 
(1724) 
16 (53) 
8 (10) 
812 
(1545) 
18 (64) 
9 (8) 
1178 
(1503) 
18 (47) 
8 (10) 
780 
(1574) 
13 (57) 
9 (10) 
981 
(1687) 
14 (74) 
8 (9) 
1085 
(1643) 
14 (70) 
8 (13) 
1132 
(2300) 
Other % 
Contacts 
Cost 
8 (23) 
6 (12) 
63 (273) 
 
3 (15) 
2 (1) 
14 (52) 
2 (9) 
1 (0) 
1 (2) 
2 (10) 
5 (2) 
10 (39) 
12 (26) 
10 (14) 
124 
(604) 
4 (15) 
11 (17) 
74 (314) 
5 (17) 
21 (25) 
146 
(498) 
3 (11) 
14 (9) 
49 (150) 
12 (26) 
10 (14) 
124 
(604) 
7 (30) 
16 (14) 
146 
(365) 
6 (21) 
10 (3) 
22 (48) 
8 (40) 
8 (8) 
50 (109) 
Total Cost 4988 
(5685) 
 
2509 
(3882) 
2980 
(3917) 
3257 
(4493) 
3786 
(5471) 
3059 
(4555) 
3438 
(4260) 
3626 
(5037) 
3786 
(5471) 
2705 
(3576) 
2796 
(3109) 
2091 
(2536) 
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Figure 1 – CONSORT diagram  
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243 referrals to 
PICuP 
74 suitable for 
the trial (30%) 
178 not suitable for 
the trial (70%) 
36 randomised 
to immediate 
therapy group 
(10 drop-outs) 
38 randomised 
to waiting list 
control group (7 
drop outs) 
83 offered therapy in 
PICuP routine service 
(47% of excluded 
patients) 
15 referred 
specifically 
for PICuP 
routine 
service only 
(8% of 
excluded 
patients) 
12 distressed 
by or unable 
to meet 
demands of 
assessments 
(7% of 
excluded 
patients) 
44 scored < 3 
on 
PANSS/not 
distressed by 
symptoms 
(25% of 
excluded 
patients) 
3 did not 
meet other 
criteria (age, 
outpatient,  
medication 
stability) (2% 
of excluded 
patients) 
5 
receiving 
other 
therapy 
(3% of 
excluded 
patients) 
4 did not 
consent to 
randomisatio
n or 6 months 
of therapy 
(2% of 
excluded 
patients) 
60 not 
interested/>
3 DNAs at 
assessment 
(34% of 
excluded 
patients) 
After 9 months, 29 of 
the 38 people received 
therapy, becoming the 
delayed therapy group 
(9 dropped-out or did 
not complete 
assessments) 
95 discharged from 
service (53% of 
excluded patients)  
 
35 
discharged 
for other 
reasons  
(20% of 
excluded 
patients) 
Figure 2: Variables where significant differences at end of therapy were not maintained at follow-up (showing average baseline values, estimated means, 
and available Ns) 
 
PANSS General 
27
27.5
28
28.5
29
29.5
30
30.5
31
31.5
32
Baseline (T:67; C:38) End (T:47; C:30) Follow-up (T:42, C:31) 
Combined therapy Control
 
BAI 
12
13
14
15
16
17
18
19
20
21
22
Baseline (T:66; C:38) End (T:44; C:30) Follow-up (T:41, C:30) 
Combined therapy Control
 
SOFAS
56
57
58
59
60
61
62
63
64
65
66
Baseline (T:63; C:34) End (T:36; C:26) Follow-up (T:35, C:25) 
Combined therapy Control
 
 BAVQ - R - Resistance
15
15.5
16
16.5
17
17.5
18
18.5
19
19.5
20
Baseline (T:43; C:26) End (T:23; C:19) Follow-up (T:21, C:20) 
Combined therapy Control
 
 
 
